Retrospective Analysis of the Factors Affecting Growth Parameters in Turkish Children With Systemic Lupus Erythematosus

Objectives: This study aims to investigate the growth parameters in Turkish children with systemic lupus erythematosus (SLE) and to compare these growth parameters according to the presence or absence of cyclophosphamide, rituximab treatment, cumulative corticosteroid dose, proliferative nephritis, and the last visit disease activity and damage index. Patients and methods: Medical data, growth parameters including z-scores for weight, height, and body mass index and parent-adjusted height z-scores of 45 juvenile SLE (jSLE) patients (5 males, 40 females; mean age 12.3±3.2 years; range 7.1 to 18 years) were retrospectively evaluated. Growth parameters were calculated by anthropometric references in Turkish children. The disease activity was assessed by the SLE Disease Activity Index 2000 (SLEDAI-2K). The disease outcome was measured by the Pediatric version of Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Results: The median diagnostic delay was two months (range, 0-36 months). The median follow-up duration was 3.21 years (range, 0.63-9.48 years). Mean height z-score was significantly lower at last visit than at the time of diagnosis. The growth parameters did not differ according to age at disease onset, diagnostic delay, presence of proliferative nephritis, having cyclophosphamide and rituximab treatment and the last visit (SLEDAI-2K) scores. The median duration of corticosteroid treatment was 3.2 years (range, 0.6-9.4 years) and the median cumulative corticosteroid dosage was 13.9 g (range, 1.9-58 g) of methylprednisolone. The mean height z-score at last visit was significantly lower in those who received at least 10 g of cumulative dose of corticosteroid. The last visit mean parent-adjusted height z-scores did not differ significantly regarding the cumulative corticosteroid dose. Conclusion: The last visit height and parent-adjusted height z-scores of jSLE patients were significantly lower. The patients treated with at least 10 g of cumulative dose of corticosteroids had lower mean height z-score.

Kaynakça

Klein-Gitelman M, Lane JC. Systemic lupus erythematosus. In: Petty R, Laxer R, Lindsley C, Wedderburn L, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Saunders; 2010. p. 285-317.

Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009;36:2539-46.

Balci S, Ekinci RMK, Bayazit AK, Melek E, Dogruel D, Altintas DU, et al. Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey. Clin Rheumatol 2019;38:1459-68.

Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:1152-9.

Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:568-73.

Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15:515-20.

Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2989-96.

Hiraki LT, Hamilton J, Silverman ED. Measuring permanent damage in pediatric systemic lupus erythematosus. Lupus 2007;16:657-62.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.

Neyzi O, Günöz H, Furman A, Bundak R, Gökçay G, Darendeliler F, et al. Türk çocuklarında vücut a¤ırlı¤ı, boy uzunlu¤u, ba çevresi ve vücut kitle indeksi referans de¤erleri. Çocuk Sa¤lı¤ı ve Hastalıkları Dergisi 2008;51:1-14.

Sahin S, Adrovic A, Barut K, Canpolat N, Ozluk Y, Kilicaslan I, et al. Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome. Lupus 2018;27:514-9.

Gulay CB, Dans LF. Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 2011;9:7.

Salah S, Lotfy HM, Mokbel AN, Kaddah AM, Fahmy N. Damage index in childhood-onset systemic lupus erythematosus in Egypt. Pediatr Rheumatol Online J 2011;9:36.

Abdalla E, Jeyaseelan L, Ullah I, Abdwani R. Growth Pattern in Children with Systemic Lupus Erythematosus. Oman Med J 2017;32:284-90.

Rygg M, Pistorio A, Ravelli A, Maghnie M, Di Iorgi N, Bader-Meunier B, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 2012;71:511-7.

Heshin-Bekenstein M, Perl L, Hersh AO, von Scheven E, Yelin E, Trupin L, et al. Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis. Pediatr Rheumatol Online J 2018;16:30.

Manaboriboon B, Silverman ED, Homsanit M, Chui H, Kaufman M. Weight change associated with corticosteroid therapy in adolescents with systemic lupus erythematosus. Lupus 2013;22:164-70.

Kaynak Göster

235 92

Arşiv
Sayıdaki Diğer Makaleler

Decreased Bilirubin is Associated With Disease Activity of Primary Sjögren's Syndrome

Jing XIE, Zhencheng ZHANG, Yan LIANG, Zaixing YANG

The Relationship Between Serum Angiogenic Factor Levels and Disease Activity in Rheumatoid Arthritis

Zahide ASLANALP, Canan TIKIZ, Aslıhan ULUSOY, Şebnem ORGUC, Aysun BİLGİ YEDEKCİ, Cevval ULMAN

The Turkish League Against Rheumatism Recommendations for the Management of Hand Osteoarthritis Under Guidance of the Current Literature and 2018 European League Against Rheumatism Recommendations

Fi̇kri̇ye Fi̇gen AYHAN, İsmihan SUNAR, Ebru UMAY, ESRA DİLEK KESKİN, Lale ALTAN, Fitnat DİNÇER, Tuncay DURUÖZ, Nazım KARALEZLİ, Tiraje TUNCER, KADRİYE BANU KURAN

The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture

Mehtap ŞAHİN, Hüseyin AYDIN, Ahmet ALTUN, Mehmet Emin DERİN, Ali ŞAHİN

The Relationship Between 99mTc-Pertechnetate Hand Perfusion Scintigraphy and Nailfold Capillaroscopy in Systemic Sclerosis Patients: A Pilot Study

Slavica PAVLOV DOLIJANOVIC, Nebojsa PETROVIC, Nada VUJASINOVIC STUPAR, Nemanja DAMJANOV, Goran RADUNOVIC, Dragan BABIC, Dragana SOBIC SARANOVIC, Vera ARTIKO

Comment on: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis

Yin WU, Zelalem NEGERI, Andrea BENEDETTI, Brett THOMBS

Efficacy of Rituximab for Refractory Pyoderma Gangrenosum-Like Ulcers in Granulomatosis With Polyangiitis Associated to Antiphospholipid Antibodies

Julia RIERA, Jorge MUSURUANA, Cecilia COSTA, Javier CAVALLASCA

Fulminant Brain Atrophy and Vasculitis on Vessel-Wall Imaging in Neuropsychiatric Lupus: Case Report and Literature Review

Mihaela Ionela SARBU, Nicolae SARBU

Joint Surgery in Tunisian Rheumatoid Arthritis Patients: Prevalence and Risk Factors

Olfa SAIDANE, Leila GAFSI, Aicha BEN TEKAYA, Ines MAHMOUD, Rawdha TEKAYA, Leila ABDELMOULA

Prevalence of Subclinical Carotid Atherosclerosis and Vitamin D Deficiency in Egyptian Ankylosing Spondylitis Patients

Dina Salem FOTOH, Dena Mamdouh SERAG, Ismail Tawfeek BADR, Dalia Salah SAIF